Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vebicorvir,ATI-2173
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ABI-H0731 (Vebicorvir) a first-generation selective inhibition of HBV DNA replication core protein, has demonstrated effective antiviral activity in chronic hepatitis B patients.
Product Name : ABI-H0731
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 06, 2022
Lead Product(s) : Vebicorvir,ATI-2173
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATI-2173,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Following 90 days of dosing, ATI-2173, in combination with tenofovir disoproxil fumarate (TDF), was generally well-tolerated with alanine aminotransferase (ALT) normalization and no ALT flares off-treatment.
Product Name : ATI-2173
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 25, 2022
Lead Product(s) : ATI-2173,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATI-2173,Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATI-2173, once-daily, oral drug candidate for treating HBV, is an investigational phosphoramidate prodrug of clevudine monophosphate, only active site polymerase inhibitor nucleotide for HBV in clinical development.
Product Name : ATI-2173
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2022
Lead Product(s) : ATI-2173,Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATI-2173,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The data showed that ATI-2173 alone, or in combination with tenofovir disoproxil fumarate (TDF), was generally well-tolerated among the cohorts, and ATI-2173 and TDF suppressed HBV DNA and induced declines in biomarkers of cccDNA activity.
Product Name : ATI-2173
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 30, 2022
Lead Product(s) : ATI-2173,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATI-2173,Vebicorvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Antios Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : ATI-2173 has, to date, demonstrated a generally well-tolerated safety profile, leveraging a unique ASPIN mechanism in clinical development to empower combination therapy.
Product Name : ATI-2173
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 19, 2021
Lead Product(s) : ATI-2173,Vebicorvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Antios Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Imdusiran,ATI-2173
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Antios Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The multi-center, double-blinded, placebo-controlled, multiple-dose cohort will evaluate the safety, pharmacokinetics, immunogenicity, and antiviral activity of the combination of ATI-2173, AB-729 and Viread.
Product Name : AB-729
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
June 30, 2021
Lead Product(s) : Imdusiran,ATI-2173
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Antios Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : ATI-2173
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The double-blind randomized controlled trial plans to enroll 30 patients and will assess the safety and efficacy of 25mg and 50mg doses of ATI-2173 in combination with tenofovir (TDF) compared with TDF plus ATI-placebo (control) in chronic HBV-infected s...
Product Name : ATI-2173
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 21, 2021
Lead Product(s) : ATI-2173
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATI-2173
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : RA Capital Management
Deal Size : $96.0 million
Deal Type : Series B Financing
Antios Therapeutics Raises $96 Million in a Series B Financing
Details : The proceeds from this financing will support the ongoing Phase 2 clinical program which is evaluating the potential for the Company’s lead clinical candidate, ATI-2173, to be a backbone of a once-daily curative regimen for chronic hepatitis B.
Product Name : ATI-2173
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 13, 2021
Lead Product(s) : ATI-2173
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : RA Capital Management
Deal Size : $96.0 million
Deal Type : Series B Financing
Lead Product(s) : ATI-2173,AB-729
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : GordonMD Global Investments
Deal Size : $75.0 million
Deal Type : Series B Financing
Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV
Details : The proceeds from this financing will be used to advance the clinical development of ATI-2173, Antios’ lead Phase 2b clinical candidate. ATI-2173 is the only Active Site Polymerase Inhibitor Nucleotide (ASPIN) in clinical development.
Product Name : ATI-2173
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 11, 2021
Lead Product(s) : ATI-2173,AB-729
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : GordonMD Global Investments
Deal Size : $75.0 million
Deal Type : Series B Financing
Lead Product(s) : ATI-2173
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The placebo-controlled Phase 1b trial evaluated the safety, tolerability, pharmacokinetics, and measurable reductions in HBV viral load of multiple oral doses of ATI-2173 in 24 patients with chronic HBV infection.
Product Name : ATI-2173
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 25, 2021
Lead Product(s) : ATI-2173
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable